Gatehouse Bio, a pioneer in next-generation therapeutics, and AstraZeneca, a global science-led biopharmaceutical company, are collaborating to explore the identification of new targets for respiratory and cardiovascular diseases using Gatehouse Bio's Artificial Intelligence powered platform, it was reported yesterday.
Gatehouse Bio's 'sRNAlytics platform' identifies novel small RNA (sRNA) signatures and illuminates molecular pathways correlated to and potentially driving disease.
Dr David W. Salzman, CEO and chief scientist, Gatehouse Bio, said, 'Our annotation library of over 1.4M small RNA features coupled with our biology-directed machine learning algorithms enable us to see signal where others have only seen noise.'
The company is collaborating with top global drug developers to incorporate their technology into discovery, research, and development programs.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study